1. Show article details.

    Chilean businessman Bilbao fined $3.2 million for insider trading

    Reuters – 1:21 PM ET 11/26/2015

    Chile's financial regulator said on Thursday it had fined Santiago-based businessman Juan Bilbao Hormaeche some $3.2 million for using insider information to trade shares of drug company CFR Pharmaceuticals SA.

  2. Show article details.

    TIMELINE-Mylan fails in $26 bln takeover bid for Perrigo

    Reuters – 12:33 PM ET 11/13/2015

    Drugmaker Mylan NV's $26 billion hostile bid for Perrigo Co Plc (PRGO) failed on Friday, putting an end to the ongoing saga, which started more than seven months ago. Netherlands-based Mylan has made a number of attempts to buy Perrigo (PRGO) but was unsuccessful in securing at least half of Perrigo (PRGO) outstanding shares in a tender offer, which expired Friday, 8.00 a.m. ET.

  3. Abbott Laboratories downgraded to neutral from buy at Goldman Sachs

    MarketWatch – 10:05 AM ET 11/13/2015
  4. Show article details.

    The high-flying health-care sector is now slowing dramatically

    MarketWatch – 3:14 PM ET 11/12/2015

    Only telecom-services companies are projected to accelerate profit growth in the current quarter. "Quarterly earnings are random events." That's what Ralph Segall said to me in a recent interview.

  5. Show article details.

    Study shows advantages of mitral valve replacement over repair

    Reuters – 1:30 PM ET 11/09/2015

    Patients with severe leakage from the mitral valve of the heart who had the valve replaced had significantly lower rates of recurrence and heart failure two years after the procedure than those who underwent surgical repair, according to data presented on Monday.

  6. Show article details.

    Zoetis Lifts Outlook as Results Top Views

    DJ Business News – 8:15 AM ET 11/03/2015

    Animal-health company Zoetis Inc. (ZTS) on Tuesday lifted its outlook for the year after reporting stronger-than-expected profit and revenue for its third quarter. For the year, Zoetis (ZTS) is now expecting $1.70 to $1.74 a share in earnings, up from its prior guidance of $1.63 to $1.68 a share. The company narrowed its revenue range to $4.7 billion to $4.75 billion.

  7. Show article details.

    Health is a Marathon, not a Sprint

    PR Newswire – 12:31 PM ET 10/30/2015

    ABBOTT PARK, Ill., Oct. 30, 2015 Well known for its culture, theater, and cuisine, New York is also one of the 25 healthiest cities in the United States. It's this fitness side that will be on show this weekend with the TCS New York City Marathon. Photo - http://photos.prnewswire.com/prnh/20151030/282292Logo - http://photos.prnewswire.com/prnh/20150928/271488LOGO.

  8. Show article details.

    'Science' Says Abbott Is a Top Employer

    PR Newswire – 3:52 PM ET 10/29/2015

    ABBOTT PARK, Ill., Oct. 29, 2015  The journal Science today recognized Abbott as a Top 20 Employer. The global healthcare company ranked No. 14 overall, receiving high marks for social responsibility, employee loyalty, and having a work culture that aligns with the values of its employees.

  9. Show article details.

    China to allow all couples two children to counter aging population

    Reuters – 2:47 PM ET 10/29/2015

    * China had already relaxed the one-child policy in 2013. * Scholars urged relaxation to ease economic restraints. * Working age population fell in 2012, first time in decades. * Shares of some baby formula makers rise. By Megha Rajagopalan and Koh Gui Qing.

  10. Show article details.

    India to press drug firms to tackle cough syrup abuse

    Reuters – 7:23 AM ET 10/27/2015

    India plans to step up pressure on pharmaceutical companies to better police supplies of codeine-based cough syrups, concerned the firms have not yet fully complied with directives more than a year old, a finance ministry official said on Tuesday.

  11. Show article details.

    Chilean in $13.2 mln insider trading accord with U.S. regulators

    Reuters – 3:32 PM ET 10/23/2015

    A former board member of Chile's CFR Pharmaceuticals SA has reached a $13.2 million settlement to resolve charges by a U.S. regulator that he engaged in insider trading ahead of Abbott Laboratories' (ABT) $2.9 billion acquisition of the drug company.

  12. Show article details.

    Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 10/22/2015

    CHICAGO, Oct. 22, 2015  InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  13. Show article details.

    Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire Young People to Donate Blood

    PR Newswire – 8:01 AM ET 10/22/2015

    JOIN THE MOVEMENT: #BETHE1DONOR TO DONATE BLOOD AND POTENTIALLY HELP SAVE A LIFE ABBOTT PARK, Ill., Oct. 22, 2015  Blood is an essential component for life, but many people do not think about it until the need is critical.

  14. Show article details.

    Abbott Labs Profit Rises

    DJ Business News – 10:55 AM ET 10/21/2015

    Abbott Laboratories Inc. said Wednesday that profit grew 7.8% in its latest quarter as results were aided by emerging markets growth. Shares rose 2.5% to $42.78 in early trading as revenue and adjusted profit edged above Wall Street's estimates. In the wake of the results, Abbott narrowed its annual guidance range for earnings per share, excluding specified items, to $2.14 to $2.16 from a previous range of $2.10 to $2.20.

  15. Show article details.

    Abbott Labs Profit Rises, Helped by Emerging Markets

    DJ Business News – 10:35 AM ET 10/21/2015

    Abbott Laboratories Inc. said Wednesday that profit grew 7.8% in its latest quarter as results were aided by emerging markets growth. Shares rose 2.5% to $42.78 in early trading as revenue and adjusted profit edged above Wall Street's estimates. In the wake of the results, Abbott narrowed its annual guidance range for earnings per share, excluding specified items, to $2.14 to $2.16 from a previous range of $2.10 to $2.20.

  16. Show article details.

    Abbott sales beat as demand for generic drugs rises

    Reuters – 8:22 AM ET 10/21/2015

    Abbott Laboratories Inc reported better-than-expected quarterly sales as demand rose for its generic drugs in emerging markets, including Latin America and China. Abbott said on Wednesday sales of its generic drugs grew in double digits in emerging markets, helped by the acquisition of Chilean drugmaker CFR Pharmaceuticals SA last year.

  17. Show article details.

    Generic drug sales drive Abbott revenue

    Reuters – 7:52 AM ET 10/21/2015

    Drugmaker Abbott Laboratories Inc reported a 2 percent rise in sales, helped by higher demand for its generic drugs in emerging markets. Net profit rose 8 percent to $580 million, or 38 cents per share, for the quarter ended Sept. 30, from $538 million, or 36 cents per share, a year earlier. Total revenue rose to $5.15 billion from $5.08 billion a year earlier.

  18. Show article details.

    Abbott Reports Third-Quarter 2015 Results

    PR Newswire – 7:45 AM ET 10/21/2015

    ABBOTT PARK, Ill., Oct. 21, 2015  Abbott today announced financial results for the third quarter ended Sept. 30, 2015.  . "Despite currency headwinds, we are on track to deliver the financial commitments we set at the beginning of the year," said Miles D. White, chairman and chief executive officer, Abbott.

  19. Show article details.

    What to Watch in the Day Ahead - Wednesday, Oct 21

    Reuters – 3:22 PM ET 10/20/2015

    Currency Chart Corner: Take a look at the FX charts with Reuters technical analyst Martin Miller. Join us for a quick round up of what the technical charts are telling us with analyst Martin Miller ...

  20. Show article details.

    Valeant Probe Reprises Federal Focus on Drug Pricing

    DJ Business News – 1:25 AM ET 10/16/2015

    Drug pricing, a key issue in the federal investigation of Valeant Pharmaceuticals International Inc. (VRX), has been a frequent focus of federal prosecutions and whistleblower lawsuits in recent years. Pharmaceutical companies have paid more than $3 billion in fines to resolve pricing cases over the past decade, according to Patrick Burns, co-director of Taxpayers Against Fraud, a group that promotes whistleblowing. Valeant said late Wednesday that it had received subpoenas...


Today's and Upcoming Events

  • Jan

    ABT to announce Q4 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Oct

    ABT Earnings Conference Call at 9:00 AM Listen

  • Oct

    ABT ex-Dividend for $0.24 on 10/13/2015

    • Announce Date: 9/17/2015
    • Record Date: 10/15/2015
    • Pay Date: 11/15/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.